Oncology

Original Paper

Antitumor Therapeutic Effect of Neurotropin on Transplanted Tumors in Rats

Mizushima Y.a,c · Wepsic H.T.a,b · Kobayashi H.c

Author affiliations

aDepartment of Pathology, Loyola University Medical Center, Maywood, Ill.; bDepartment of Laboratory Services, Edward J. Hines, Jr. Veterans Administration Hospital, Hines, Ill.; USA; claboratory of Pathology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan

Related Articles for ""

Oncology 1984;41:289–292

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: June 17, 2009
Issue release date: 1984

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

The antitumor therapeutic effect of neurotropin (NSP) was examined using the moderately immunogenic KMT-17 tumor in WKA rats and the lower immunogenic 9098 tumor in ACI rats. Treatment with NSP was effective in causing tumor regression and of prolonging the mean survival time of animals which were inoculated with the KMT-17 tumor whereas it is ineffective with the 9098 tumor. Mitogen studies with 9098 tumor-bearing animals, which were treated with NSP, showed that the PHA-P mitogenic reactivity of spleen cells from NSP treated tumor bearing rats (TBR) was higher than that from NSP untreated TBR. When 9098 tumor bearing animals were given combination therapy with NSP and adriamycin (ADR), a beneficial therapeutic effect of NSP was observed. No adverse effect of NSP treatment was observed when it was given before, intermediate or after ADR treatment. These experiments demonstrate that immunomodulation by NSP may possibly have a beneficial therapeutic effect on tumor growth but the conditions to demonstrate this may be highly variable.

© 1984 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: June 17, 2009
Issue release date: 1984

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP